Savara enters master services agreement with Fujifilm for molgramostim manufacturing

Savara Inc

Agreement covers development and manufacturing services for molgramostim active pharmaceutical ingredient.
Scope of Work #03 executed for Process Performance Qualification manufacturing campaign.
Either party may terminate with three months' notice if no scope-of-work activities are in process.
Termination also allowed for material uncured breach or unforeseen technical issues by Fujifilm.
Includes standard provisions on confidentiality, intellectual property, liability, and indemnification.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Savara Inc entered into Master Services Agreement with Fujifilm Diosynth Biotechnologies UK Limited, Fujifilm Diosynth Biotechnologies Texas, LLC, and Fujifilm Diosynth Biotechnologies U.S.A., Inc. (collectively, “Fujifilm”) (effective 2024-02-13).

Action: entry
Counterparty: Fujifilm Diosynth Biotechnologies UK Limited, Fujifilm Diosynth Biotechnologies Texas, LLC, and Fujifilm Diosynth Biotechnologies U.S.A., Inc. (collectively, “Fujifilm”)
Effective: 2024-02-13

Exact text from the filing

On February 13, 2024, Savara Inc. (the “Company”) entered into a Master Services Agreement (the “Agreement”) with Fujifilm Diosynth Biotechnologies UK Limited, Fujifilm Diosynth Biotechnologies Texas, LLC, and Fujifilm Diosynth Biotechnologies U.S.A., Inc. (collectively, “Fujifilm”), pursuant to which Fujifilm will continue to provide development and manufacturing services related to active pharmaceutical ingredient for the Company’s molgramostim product candidate in accordance with the terms of separate scope of work agreements to be entered into by the parties.

View on SEC.gov

Browse all material agreements →

Savara Inc filing history →

Source: SEC EDGAR

accession 0001193125-24-038108

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.